[Biopharmaceutical and clinico-pharmacological research on the intramammary preparation Cephamasten].

An animal drug formula, Cephamasten, for intramammary application in the treatment of mastitis-affected cows, ewes, and goats in the lactation period was worked out on the base of microbiologic, technologic, biopharmaceutic, and clinico-pharmacologic studies. Its active ingredient was the Pharmachim cephalexin-monohydrate. The consistence of Cephamasten has proved suitable for intracisternal introduction.

[Intramammary drug forms of neotil in treating mastitis during lactation].

Technological, biopharmaceutical, and clinico-pharmacological studies were carried out on the varying composition of drug formulas that included a tylosin base and neomycin sulfate, intended for the treatment of mastitis-affected cows during the lactation period. A base was developed of suitable viscosity and physico-chemical properties, that rapidly released the active ingredients included in it and made them penetrate in depth in the udder glandular tissue. Both the base and the drug formula Neotil were shown to be well tolerated.

[Treatment of bovine mastitis during the dry period and development of intramammary drug formulations].

Studied were the factors that govern the pharmacokinetics of the intracysternal introduction of therapeutic means into the dry udder (type of drug base, physical and chemical properties of the drugs themselves and the physiologic and functional status of the gland). It is stated that the development of intramammary drug formulas for cows in a dry period is a difficult and complex activity as it is associated with the requirement to overcome two main conditions that could hardly be combined from the standpoint of biopharmacy and pharmacology. These consist in that the need of high concentrations to produce a therapeutic effect is connected with the presence of active ingredients that can be readily released from the base, while the need of producing also of a prophylactic effect imposes the persistence of these concentrations in the glandular secretion, and this means that the active matter should be slowly released.